Lupin Completes Acquisition of VISUfarma to Expand Ophthalmology Portfolio
On April 2, 2026, Lupin Limited, a leading global pharmaceutical company based in Mumbai, announced its successful acquisition of VISUfarma B.V., a prominent player in the European ophthalmology sector. This acquisition marks a significant strategic move for Lupin, positioned to bolster its Specialty Care portfolio and enhance its presence across Europe.
VISUfarma, known for its robust range of ophthalmological products, now adds to Lupin's existing portfolio of over 60 brands catering to various eye-related health needs. The newly acquired offerings will support treatments in areas such as dry eyes, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialized dietary supplements. The integration of VISUfarma's products significantly broadens Lupin's reach in major European markets, including Italy, the United Kingdom, Spain, Germany, and France. The transition is backed by VISUfarma's deeply experienced team, which brings valuable expertise in ophthalmology, well-established connections, and localized market intelligence.
The global demand for innovative ophthalmic solutions is on the rise, propelled mainly by the aging population and a surge in diabetic eye diseases, placing Lupin in a prime position to meet these needs. Vinita Gupta, CEO of Lupin, remarked on this acquisition, stating, "This milestone not only enhances our portfolio with over 60 innovative eye health products supported by an established commercial infrastructure but is also expected to increase our value and accelerate our growth in the Specialty segment." Gupta further emphasized the strategic importance of this move, aligning with Lupin's vision of addressing eye health needs amidst evolving global healthcare challenges.
Paolo Cioccetti, Managing Director of VISUfarma Italy, expressed enthusiasm about the collaboration, saying, "We are thrilled to embark on this new chapter with Lupin. Their global experience, vision, and commitment to ophthalmology make them the ideal partner to elevate VISUfarma to the next level. Together, we believe we can make a substantial contribution to the advancement of ophthalmic care in Europe and beyond."
The acquisition of VISUfarma underscores Lupin’s ambition to further establish its footprint and capabilities within the ophthalmology market while continuing its commitment to improving patient health outcomes. As a company with a presence in over 100 markets, Lupin specializes in a wide range of pharmaceutical products, including brand and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With 15 state-of-the-art manufacturing facilities and a network of research centers, the company employs over 24,000 dedicated professionals committed to delivering patient-centered solutions.
Lupin’s dedication to the healthcare sector is reflected not only in its product offerings but also through its subsidiaries, such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, all focused on enhancing patient health. The acquisition of VISUfarma presents an exciting opportunity for Lupin to leverage new synergies, ultimately leading to better eye care solutions for patients worldwide.
To learn more about Lupin, visit www.lupin.com or follow them on LinkedIn at https://www.linkedin.com/company/lupin.
VISUfarma, known for its robust range of ophthalmological products, now adds to Lupin's existing portfolio of over 60 brands catering to various eye-related health needs. The newly acquired offerings will support treatments in areas such as dry eyes, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialized dietary supplements. The integration of VISUfarma's products significantly broadens Lupin's reach in major European markets, including Italy, the United Kingdom, Spain, Germany, and France. The transition is backed by VISUfarma's deeply experienced team, which brings valuable expertise in ophthalmology, well-established connections, and localized market intelligence.
The global demand for innovative ophthalmic solutions is on the rise, propelled mainly by the aging population and a surge in diabetic eye diseases, placing Lupin in a prime position to meet these needs. Vinita Gupta, CEO of Lupin, remarked on this acquisition, stating, "This milestone not only enhances our portfolio with over 60 innovative eye health products supported by an established commercial infrastructure but is also expected to increase our value and accelerate our growth in the Specialty segment." Gupta further emphasized the strategic importance of this move, aligning with Lupin's vision of addressing eye health needs amidst evolving global healthcare challenges.
Paolo Cioccetti, Managing Director of VISUfarma Italy, expressed enthusiasm about the collaboration, saying, "We are thrilled to embark on this new chapter with Lupin. Their global experience, vision, and commitment to ophthalmology make them the ideal partner to elevate VISUfarma to the next level. Together, we believe we can make a substantial contribution to the advancement of ophthalmic care in Europe and beyond."
The acquisition of VISUfarma underscores Lupin’s ambition to further establish its footprint and capabilities within the ophthalmology market while continuing its commitment to improving patient health outcomes. As a company with a presence in over 100 markets, Lupin specializes in a wide range of pharmaceutical products, including brand and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With 15 state-of-the-art manufacturing facilities and a network of research centers, the company employs over 24,000 dedicated professionals committed to delivering patient-centered solutions.
Lupin’s dedication to the healthcare sector is reflected not only in its product offerings but also through its subsidiaries, such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, all focused on enhancing patient health. The acquisition of VISUfarma presents an exciting opportunity for Lupin to leverage new synergies, ultimately leading to better eye care solutions for patients worldwide.
To learn more about Lupin, visit www.lupin.com or follow them on LinkedIn at https://www.linkedin.com/company/lupin.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.